Australia markets closed

SAVA Jan 2024 135.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
120.040.00 (0.00%)
As of 09:13AM EST. Market open.
Full screen
Previous close120.04
Expiry date2024-01-19
Day's range120.04 - 120.04
Contract rangeN/A
Open interest9
  • GlobeNewswire

    Cassava Sciences Appoints Three New Members to its Board of Directors

    Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i

  • Simply Wall St.

    Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

    With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...

  • GlobeNewswire

    Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

    Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected approximately mid-year 2025.MRI safety data suggests simufilam is not associated with ARIA.$142.4 Million in cash and cash equivalents at September 30, 2023. AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc